849 related articles for article (PubMed ID: 17206155)
1. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
Sergina NV; Rausch M; Wang D; Blair J; Hann B; Shokat KM; Moasser MM
Nature; 2007 Jan; 445(7126):437-41. PubMed ID: 17206155
[TBL] [Abstract][Full Text] [Related]
2. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
3. Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?
Menendez JA; Lupu R
Breast Cancer Res; 2007; 9(5):111. PubMed ID: 17983482
[TBL] [Abstract][Full Text] [Related]
4. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
[TBL] [Abstract][Full Text] [Related]
5. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
6. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
Kong A; Calleja V; Leboucher P; Harris A; Parker PJ; Larijani B
PLoS One; 2008 Aug; 3(8):e2881. PubMed ID: 18682844
[TBL] [Abstract][Full Text] [Related]
7. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
Tao JJ; Castel P; Radosevic-Robin N; Elkabets M; Auricchio N; Aceto N; Weitsman G; Barber P; Vojnovic B; Ellis H; Morse N; Viola-Villegas NT; Bosch A; Juric D; Hazra S; Singh S; Kim P; Bergamaschi A; Maheswaran S; Ng T; Penault-Llorca F; Lewis JS; Carey LA; Perou CM; Baselga J; Scaltriti M
Sci Signal; 2014 Mar; 7(318):ra29. PubMed ID: 24667376
[TBL] [Abstract][Full Text] [Related]
8. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
9. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells.
Amin DN; Sergina N; Lim L; Goga A; Moasser MM
Biochem J; 2012 Nov; 447(3):417-25. PubMed ID: 22853430
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
[TBL] [Abstract][Full Text] [Related]
11. Targeting HER proteins in cancer therapy and the role of the non-target HER3.
Hsieh AC; Moasser MM
Br J Cancer; 2007 Aug; 97(4):453-7. PubMed ID: 17667926
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.
Garrett JT; Olivares MG; Rinehart C; Granja-Ingram ND; Sánchez V; Chakrabarty A; Dave B; Cook RS; Pao W; McKinely E; Manning HC; Chang J; Arteaga CL
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):5021-6. PubMed ID: 21385943
[TBL] [Abstract][Full Text] [Related]
13. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
14. Unnatural polyketide analogues selectively target the HER signaling pathway in human breast cancer cells.
Kwon SJ; Kim MI; Ku B; Coulombel L; Kim JH; Shawky JH; Linhardt RJ; Dordick JS
Chembiochem; 2010 Mar; 11(4):573-80. PubMed ID: 20058253
[TBL] [Abstract][Full Text] [Related]
15. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
[TBL] [Abstract][Full Text] [Related]
16. Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.
Shankaran H; Zhang Y; Tan Y; Resat H
PLoS Comput Biol; 2013; 9(8):e1003201. PubMed ID: 23990774
[TBL] [Abstract][Full Text] [Related]
17. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
Münster PN; Marchion DC; Basso AD; Rosen N
Cancer Res; 2002 Jun; 62(11):3132-7. PubMed ID: 12036925
[TBL] [Abstract][Full Text] [Related]
18. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
Serra V; Scaltriti M; Prudkin L; Eichhorn PJ; Ibrahim YH; Chandarlapaty S; Markman B; Rodriguez O; Guzman M; Rodriguez S; Gili M; Russillo M; Parra JL; Singh S; Arribas J; Rosen N; Baselga J
Oncogene; 2011 Jun; 30(22):2547-57. PubMed ID: 21278786
[TBL] [Abstract][Full Text] [Related]
19. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
20. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.
Chakrabarty A; Sánchez V; Kuba MG; Rinehart C; Arteaga CL
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2718-23. PubMed ID: 21368164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]